Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: cabazitaxel

« Back to Dashboard

Cabazitaxel is the generic ingredient in one branded drug marketed by Sanofi Aventis Us and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for cabazitaxel. One supplier is listed for this compound.

Summary for Generic Name: cabazitaxel

Tradenames:1
Patents:6
Applicants:1
NDAs:1
Drug Master File Entries: see list11
Suppliers: see list1

Clinical Trials for: cabazitaxel

Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)
Status: Recruiting Condition: Urothelium Transitional Cell Carcinoma

Cabazitaxel - PF Induction Chemotherapy
Status: Recruiting Condition: Squamous Cell Carcinoma of the Head and Neck

Study of Weekly Cabazitaxel for Advanced Prostate Cancer
Status: Active, not recruiting Condition: Hormone Refractory Prostate Cancer

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer
Status: Recruiting Condition: Prostate Cancer

Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
Status: Terminated Condition: Neoplasms, Malignant

Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer
Status: Withdrawn Condition: Castrate-resistant Metastatic Prostate Cancer

Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy
Status: Active, not recruiting Condition: Urothelial Carcinoma

Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer
Status: Terminated Condition: Prostate Cancer; Prostatic Neoplasms

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder
Status: Not yet recruiting Condition: Urothelial Carcinoma of the Urinary Bladder

A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse
Status: Recruiting Condition: Adenocarcinoma of Prostate; Progression of Prostate Cancer

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes6,331,635<disabled>YY<disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes7,241,907<disabled>Y<disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes5,438,072<disabled>Y<disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes6,372,780<disabled><disabled>
Sanofi Aventis Us
JEVTANA KIT
cabazitaxel
SOLUTION;IV (INFUSION)201023Jun 17, 2010RXYes6,387,946<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc